AI Tool Comparison

Comparing as AI Medical Imaging & Diagnostics
PathAI vs Paige

PathAI

Enterprise

Visit Website Full Review

Paige

Enterprise

Visit Website Full Review

Verdict by Category

Detailed category analysis is not available for this comparison.

View PathAI View Paige

Feature & Spec Matrix

Detailed Comparison23 Criteria

Complete side-by-side breakdown of specifications, capabilities, and feature parity

Swipe horizontally to compare features

Feature / Spec

PathAI

Paige

Pricing Model

EnterpriseAI pathology solutions for biopharma — Custom enterprise partnership agreements only

EnterpriseAI clinical pathology diagnostics — Institutional and hospital laboratory enterprise licensing

Starting Price

Custom / Contact Sales

Free Plan & Trial Scope

Difference

No free plan — enterprise and biopharma contracts only; acquired by Roche in May 2026

No free plan — enterprise hospital and biopharma contracts via sales team

User Rating Score

Unrated

Ideal Workflow / Use Case

Difference

Hospital pathology labs and biopharma companies needing AI-powered digital pathology for oncology diagnostics, companion diagnostic development, and clinical trial tissue analysis

Cancer centers, hospital pathology labs, and biopharma companies needing FDA-cleared AI for prostate and breast cancer diagnosis, digital pathology viewing, and biomarker research

Enterprise & Scalability

Difference

HIPAA compliant, CAP/CLIA certified lab services, FDA 510k cleared algorithms, SOC 2 Type II, full enterprise LIS/PACS integration, dedicated implementation and scientific support, biopharma research service contracts, and 450+ pathologist annotation network

FDA 510k cleared primary diagnosis AI, CE marked, HIPAA compliant, SOC 2 Type II, CAP/CLIA compatible lab workflows, HL7/FHIR integration, GPU infrastructure with 10+ petaFLOPS AIRI compute, enterprise pathology scanner compatibility (Leica Aperio, Hamamatsu NanoZoomer, Philips IntelliSite), and dedicated implementation support

Core Categories

AI Healthcare ToolsAI Research & Education Tools

AISight — cloud-native digital pathology image management, analysis, and collaboration platform

Supported

20+ FDA-cleared and research-grade AI algorithms for oncology and liver disease

Difference

PathAI Advantage

Not listed

32.5M+ expert pathologist annotations — one of the largest training datasets in pathology AI

Difference

PathAI Advantage

Not listed

AIM-HER2 Breast Cancer algorithm for automated HER2 scoring with aMIL heatmaps

Supported

PathExplore panel of human interpretable features (HIFs) for tumor microenvironment research

Difference

PathAI Advantage

Not listed

Companion diagnostics development in partnership with major pharma companies

Supported

CLIA-certified lab services for biopharma clinical trial tissue analysis

Difference

PathAI Advantage

Not listed

Whole slide image (WSI) management with scanner-neutral compatibility

Supported

Acquired by Roche in May 2026 — now backed by global diagnostic infrastructure

Difference

PathAI Advantage

Not listed

Partnerships with Moffitt Cancer Center, University Hospital Zurich, Bristol-Myers Squibb, and Merck

Difference

PathAI Advantage

Not listed

Paige Prostate — FDA-cleared AI for prostate cancer detection and Gleason grading

Difference

Not listed

Paige Advantage

First ever FDA clearance for AI in primary pathology diagnosis — historic regulatory milestone

Difference

Not listed

Paige Advantage

First CE mark in AI pathology — cleared for clinical use across EU member states

Difference

Not listed

Paige Advantage

AIRI infrastructure with 10+ petaFLOPS GPU compute for large-scale model training

Difference

Not listed

Paige Advantage

1.2M+ slide digital archive from Memorial Sloan Kettering for model training

Difference

Not listed

Paige Advantage

Spinout from Memorial Sloan Kettering with exclusive access to MSK's pathology IP and 25M+ slides

Difference

Not listed

Paige Advantage

PathAI Pros & Cons

Pros

Acquired by Roche (May 2026) — now backed by the world's largest diagnostics company
32.5M+ expert annotations — one of the world's largest pathology AI training datasets
20+ AI algorithms covering oncology, liver disease, and tumor microenvironment analysis
AISight is scanner-neutral — works with Leica, Hamamatsu, Philips scanners with FDA clearance
CLIA-certified lab services for biopharma clinical trial support
Partnerships with BMS, Merck, Moffitt Cancer Center, and University Hospital Zurich
First AI pathology company recognized as a leader in CB Insights Digital Pathology market map

Cons

Acquired by Roche in May 2026 — future product roadmap and independent operations may change
Enterprise and biopharma-focused — not accessible to independent pathologists or small labs
No self-serve pricing or trial — all engagements are through enterprise procurement
Requires digital pathology infrastructure (scanners, storage, LIS integration)
Integration complexity for labs not yet on digital pathology workflows

Paige Pros & Cons

Pros

First FDA clearance for AI in primary pathology diagnosis — a historic regulatory milestone
First CE mark for AI pathology in Europe — validated for clinical use across EU
Founded on MSK's 25M+ pathology slides — the richest cancer pathology training set in the world
AIRI infrastructure with 10+ petaFLOPS — enterprise-grade AI compute at clinical scale
FullFocus viewer is scanner-neutral with FDA clearances for Leica, Hamamatsu, and Philips
The most credentialed AI pathology company in terms of regulatory approvals
Backed by Goldman Sachs, Breyer Capital, and Healthcare Venture Partners

Cons

Enterprise and institutional access only — not available to small or independent pathology labs
No published pricing — all contracts negotiated through enterprise procurement
Requires digital pathology infrastructure — scanners, storage, and LIS integration
Pathologist review and sign-off still required for all AI-generated results
Focused on pathology and oncology — not a general medical imaging platform

Head-to-Head Battle Cards